Mubadala, CBC Group Acquire UCB’s Business in China
The acquisition includes UCB’s neurology and allergy portfolios and the Zhuhai manufacturing site.
Abu Dhabi's state investor Mubadala Investment Company, in partnership with Asia's largest healthcare investment firm CBC Group, has acquired 100% ownership of UCB Pharma’s business in China.[1]
UCB, a Belgian biopharmaceutical firm, has a presence in China’s immunology, neurology, and rare disease markets, focusing on Central Nervous System drugs.
The acquisition includes UCB’s neurology and allergy portfolios and the Zhuhai manufacturing site, with 2023 net sales of €131 million ($146.19 million).
This move is part of Mubadala's strategy to expand in Asia's healthcare sector and is expected to close in the fourth quarter (Q4) of 2024, pending regulatory approvals.
Jean-Christophe Tellier, CEO at UCB, mentioned that UCB is considering the introduction of new medicines in immunology, neurology, and rare diseases in China.
